ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis

BACKGROUND: Patient outcomes were assessed based on a pre-biopsy ExoDx Prostate (EPI) score at 2.5 years of the 5-year follow-up of ongoing prostate biopsy Decision Impact Trial of the ExoDx Prostate (IntelliScore). METHODS: Prospective, blinded, randomized, multisite clinical utility study was cond...

Descripción completa

Detalles Bibliográficos
Autores principales: Tutrone, Ronald, Lowentritt, Ben, Neuman, Brian, Donovan, Michael J., Hallmark, Elliot, Cole, T. Jeffrey, Yao, Yiyuan, Biesecker, Claire, Kumar, Sonia, Verma, Vinita, Sant, Grannum R., Alter, Jason, Skog, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449627/
https://www.ncbi.nlm.nih.gov/pubmed/37193776
http://dx.doi.org/10.1038/s41391-023-00675-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449627/
https://www.ncbi.nlm.nih.gov/pubmed/37193776
http://dx.doi.org/10.1038/s41391-023-00675-1

Ejemplares similares